| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.034 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |